<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:chebi fb="2" ids="35475">Non-steroidal anti-inflammatory drugs</z:chebi> use may protect against development of oesophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>AIM: To define the consequences of <z:chebi fb="2" ids="35475">non-steroidal anti-inflammatory drugs</z:chebi> use in patients with <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Records of <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e>/oesophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> patients examined in Blackpool-Wyre-Fylde area were reviewed </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> surviving patients completed validated questionnaires </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Use of <z:chebi fb="2" ids="35475">non-steroidal anti-inflammatory drugs</z:chebi> of any type and at any frequency was more prevalent in <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> patients [147 (38%) <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> vs. 30 (26%) oesophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp>, P = 0.02] </plain></SENT>
<SENT sid="5" pm="."><plain>Daily use of <z:chebi fb="2" ids="35475">non-steroidal anti-inflammatory drugs</z:chebi> was more prevalent in <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> patients [88 (23%) <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> vs. 14 (12%) oesophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp>, P = 0.02], due to more prevalent consumption of non-aspirin <z:chebi fb="2" ids="35475">non-steroidal anti-inflammatory drugs</z:chebi> [48 (13%) <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> vs. four (4%) oesophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp>, P = 0.009] </plain></SENT>
<SENT sid="6" pm="."><plain>There was no difference between the two groups in usage of either daily low-dose aspirin or of occasional <z:chebi fb="2" ids="35475">non-steroidal anti-inflammatory drugs</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>In logistic regression analysis any use of <z:chebi fb="2" ids="35475">non-steroidal anti-inflammatory drugs</z:chebi> [odds ratio (OR) = 0571 (95% CI: 0.359-0.909), P = 0.018] and daily use of non-aspirin <z:chebi fb="2" ids="35475">non-steroidal anti-inflammatory drugs</z:chebi> [OR = 0.297 (95% CI: 0.097-0.911), P = 0.034] were significant protective factors </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="2" ids="35475">Non-steroidal anti-inflammatory drugs</z:chebi> use did not affect the survival of oesophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> patients </plain></SENT>
<SENT sid="9" pm="."><plain>Oesophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> and <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> consuming <z:chebi fb="2" ids="35475">non-steroidal anti-inflammatory drugs</z:chebi> did not differ in upper <z:hpo ids='HP_0002239'>gastrointestinal bleeding</z:hpo> [26 (15%) <z:chebi fb="2" ids="35475">non-steroidal anti-inflammatory drugs</z:chebi> consumers vs. 29 (9%) non-consumers, P = 0.08], oesophageal <z:mpath ids='MPATH_579'>ulcers</z:mpath> [31 (18%) <z:chebi fb="2" ids="35475">non-steroidal anti-inflammatory drug</z:chebi> consumers vs. 49 (15%) non-consumers, P = 0.43] or stricturing [19 (11%) <z:chebi fb="2" ids="35475">non-steroidal anti-inflammatory drug</z:chebi> consumers vs. 41 (13%) non-consumers, P = 0.58] </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: (i) Daily use of <z:chebi fb="2" ids="35475">non-steroidal anti-inflammatory drugs</z:chebi> is more prevalent in <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> than oesophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> patients, because of a more prevalent use of non-aspirin <z:chebi fb="2" ids="35475">non-steroidal anti-inflammatory drugs</z:chebi> </plain></SENT>
<SENT sid="11" pm="."><plain>(ii) Use of <z:chebi fb="2" ids="35475">non-steroidal anti-inflammatory drugs</z:chebi> in <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> patients is safe if acid suppression is adequate </plain></SENT>
</text></document>